Clinical trials: Depressive; Behavioral Disorder
Major Depressive Disorder (MDD)
Effects of Antidepressants on Sexual Functioning
The purpose of this trial is to study the effects of two depression medications on sexual functioning.
- Trial name
- NCT00051259
- Testing
- Extended-Release Bupropion Hydrochloride
- Where
- 23 sites in United States
- Volunteers
- 420 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder
An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder
The purpose of the study is to evaluate the efficacy of saredutant in the treatment of Major Depressive Disorder in elderly patients.To evaluate the tolerability, safety and efficacy on disability and quality of life in patients…
- Trial name
- NCT00415142
- Testing
- saredutant (SR48968), escitalopram
- Where
- 8 sites in United States, Croatia and 6 more
- Volunteers
- 393 people
- Sponsor
- Sanofi
Depressive Disorder
rEEG Guided Pharmacotherapy of Subjects With Depression Treatment Failure
This study is testing a process (rEEG)for selecting the most appropriate medication(s) to treat a patient's depression versus a control group being treated according to a standardized method, the modified Star*D Algorithm.
- Trial name
- NCT00437827
- Testing
- Star*D algorithm, rEEG-guided therapy
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- MYnd Analytics
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Schizophrenia
Four Dimensions in Schizophrenia
Observational, non-interventional, longitudinal, prospective,multicenter, open label (No treatment is involved). 4 assessment will be carried out , in months 0, 1, 3 and 6.
- Trial name
- 4D (NCT00782899)
- Where
- 65 sites in Spain
- Volunteers
- 320 people
- Sponsor
- AstraZeneca
Major Depressive Disorder (MDD)
A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder
The purpose of this randomized, double-blind, placebo-controlled study is to assess the safety and efficacy of PRX-00023 in patients with major depressive disorder.
- Trial name
- NCT00448292
- Testing
- PRX-00023
- Where
- 21 sites in United States
- Volunteers
- 330 people
- Sponsor
- Epix Pharmaceuticals, Inc.
Major Depressive Disorder
Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
The clinical trial will investigate the effect of brexpiprazole on the concept of life engagement in participants with Major Depressive Disorder (MDD) with a current depressive episode.
- Trial name
- NCT04830215
- Testing
- Brexpiprazole
- Where
- Canada
- Volunteers
- 122 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Chronic Kidney Disease Stage V, Hemodialysis
Post Marketing Observational Study on Paricalcitol IV Administered to Venezuelan Patients
This study was designed to evaluate the effectiveness, safety, and impact on quality of life when paricalcitol (Zemplar® intravenous [IV]) is administered in Venezuelan patients on hemodialysis who are at risk of developing…
- Trial name
- NCT01758289
- Where
- 8 sites in Venezuela
- Volunteers
- 105 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Major Depressive Disorder \(MDD, Depressive Disorder, Major
Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Major Depressive Disorder (MDD)
Trial title: A Randomized, Double Blind Sham Controlled Clinical Trial to Evaluate the Efficacy of Electrical Vestibular Nerve Stimulation (VeNS), Compared to a Sham Control for Treatment of Major Depressive Disorder (MDD) …
- Trial name
- NCT06470035
- Testing
- Active VeNS Device
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 170 people
- Sponsor
- Neurovalens Ltd.
Major Depressive Disorder
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms
The purpose of this study is to evaluate the efficacy and overall safety and tolerability of treatment with adjunctive JNJ-40411813 compared to placebo in patients with MDD with anxiety symptoms being treated with an…
- Trial name
- NCT01582815
- Testing
- JNJ-40411813
- Where
- 26 sites in Bulgaria, Hungary and 4 more
- Volunteers
- 121 people
- Sponsor
- Janssen Research & Development, LLC
Depression / Major Depressive Disorder, Depressed Mood
REM Sleep Disruption and Its Potential Uses in Depression Management
This randomized study evaluated whether brief wrist vibrations delivered through an Apple Watch during algorithm-identified rapid eye movement (REM) sleep could reduce depressive symptoms over approximately four weeks.
- Trial name
- NCT07891806
- Testing
- REM-Contingent Smartwatch Haptic Stimulation, Smartwatch Sleep Monitoring and Smart Alarm
- Where
- 2 sites in Romania
- Volunteers
- 208 people
- Sponsor
- WAKEZ HEALTH TECH ECOSYSTEM SRL
Treatment Resistant Depression
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale…
- Trial name
- RECOVER (NCT03887715)
- Testing
- Vagus Nerve Stimulation (VNS)
- Where
- 101 sites in United States
- Volunteers
- 6,800 people
- Sponsor
- LivaNova
Treatment-resistant Depression
A Trial of GH001 in Patients With Treatment-resistant Depression
The aim of this randomized, double-blind, placebo-controlled, phase 2b clinical trial is to investigate the safety and efficacy of GH001 (containing mebufotenin [5-methoxy-N,N-dimethyltryptamine; 5-MeO-DMT]) in patients with…
- Trial name
- NCT05800860
- Testing
- GH001
- Where
- 11 sites in Czechia, Germany and 4 more
- Volunteers
- 81 people
- Sponsor
- GH Research Ireland Limited